SEC 13F Intelligence

Managers / Q3 2022 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$1.8B
Q3 2022
Positions
73
Filings on Record
27
2019–present window
Filed
Nov 14, 2022
original filing

Summary

Boxer Capital, LLC reported $1.8B in U.S.-listed holdings across 73 positions for Q3 2022.

Its largest position, MRTXEUR, represents 7.9% of the portfolio.

Compared with Q2 2022, the fund opened 6 new positions and exited 9.

Portfolio Metrics

Turnover
+12.7%
vs prior filed quarter
Top-10 Concentration
+47.2%
share of reported value
Largest Position
+7.9%
Mirati Therapeutics
New / Exited
6 / 9
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 82.6%Other: 13.2%ADR: 4.2%Equity WRT: 0.0%
  • Common Stock · 82.6% · $1.5B
  • Other · 13.2% · $235M
  • ADR · 4.2% · $74M
  • Equity WRT · 0.0% · $56,000

Quarter-over-Quarter Changes full breakdown →

vs Q2 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
VTYXUSDVENTYX BIOSCIENCES INCNEW+850.0K850.0K+$30M$30M
VERUEURVERU INCNEW+2.50M2.50M+$29M$29M
EX9EXELIXIS INCNEW+1.25M1.25M+$20M$20M
THIRD HARMONIC BIO INCNEW+570.4K570.4K+$11M$11M
ALTALTIMMUNE INCNEW+500.0K500.0K+$6M$6M
ALAUNOS THERAPEUTICS INCNEW+1.50M1.50M+$3M$3M
Turning Point Therapeutics ISOLD OUT−570.7K0−$43M$0
SPDR SER TRSOLD OUT−500.0K0−$37M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2022

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MRTXEURMIRATI THERAPEUTICS INChistory →COM7.86%$140M2.00M
2CYTKCYTOKINETICS INChistory →COM NEW5.72%$102M2.10M
3PROMETHEUS BIOSCIENCES INCCOM5.69%$101M1.71M
4SWTXUSDSPRINGWORKS THERAPEUTICS INChistory →COM5.49%$98M3.42M
5APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM5.01%$89M1.30M
6RVMDREVOLUTION MEDICINES INChistory →COM4.42%$79M3.98M
7ONCBEIGENE LTDhistory →SPONSORED ADR3.79%$67M500.0K
8AMLXAMYLYX PHARMACEUTICALS INChistory →COM3.30%$59M2.08M
9TYRATYRA BIOSCIENCES INChistory →COM3.19%$57M6.45M
10RLAYRELAY THERAPEUTICS INChistory →COM2.73%$49M2.17M
11SG7SAGE THERAPEUTICS INChistory →COM2.41%$43M1.09M
12GOSSGOSSAMER BIO INChistory →COM2.41%$43M3.57M
132662247DITEOS THERAPEUTICS INChistory →COM2.31%$41M2.15M
14MERUS N VCOM2.14%$38M1.90M
15PMVPPMV PHARMACEUTICALS INChistory →COM2.12%$38M3.16M
16RCUSARCUS BIOSCIENCES INChistory →COM2.11%$37M1.43M
17BLUBELLUS HEALTH INC NEWhistory →COM NEW1.90%$34M3.20M
18ANABANAPTYSBIO INChistory →COM1.87%$33M1.30M
19IDYAIDEAYA BIOSCIENCES INChistory →COM1.85%$33M2.20M
20RETAEURREATA PHARMACEUTICALS INChistory →CL A1.75%$31M1.24M
21VTYXUSDVENTYX BIOSCIENCES INChistory →COM1.67%$30M850.0K
22VERUEURVERU INChistory →COM1.62%$29M2.50M
23AKROAKERO THERAPEUTICS INChistory →COM1.59%$28M831.5K
24TNGXTANGO THERAPEUTICS INChistory →COM1.40%$25M6.87M
25AM6AMICUS THERAPEUTICS INChistory →COM1.37%$24M2.33M
26DAWNGBXDAY ONE BIOPHARMACEUTICALS Ihistory →COM1.34%$24M1.19M
27NUVLNUVALENT INChistory →COM1.32%$24M1.21M
28RCKTROCKET PHARMACEUTICALS INChistory →COM1.32%$23M1.47M
29SRPTSAREPTA THERAPEUTICS INChistory →COM1.24%$22M200.0K
30XENEXENON PHARMACEUTICALS INChistory →COM1.22%$22M600.0K
31ACADACADIA PHARMACEUTICALS INChistory →COM1.16%$21M1.26M
32EX9EXELIXIS INChistory →COM1.10%$20M1.25M
33POINT BIOPHARMA GLOBAL INCCOM1.09%$19M2.50M
34IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM1.04%$19M1.94M
35RNAGBPAVIDITY BIOSCIENCES INChistory →COM1.03%$18M1.12M
36KNTEUSDKINNATE BIOPHARMA INChistory →COM1.02%$18M1.52M
37PROTHENA CORP PLCSHS1.02%$18M300.0K
382655787DBLUEPRINT MEDICINES CORPhistory →COM1.02%$18M275.0K
39NRIXNURIX THERAPEUTICS INChistory →COM0.90%$16M1.22M
40CGEMCULLINAN ONCOLOGY INChistory →COM0.77%$14M1.07M
41THIRD HARMONIC BIO INCCOM0.61%$11M570.4K
42ETNBGBP89BIO INCCOM0.46%$8M1.40M
43FATEFATE THERAPEUTICS INCCOM0.44%$8M350.0K
44ASCENDIS PHARMA A/SSPONSORED ADR0.41%$7M70.0K
45TSVT*2SEVENTY BIO INCCOMMON STOCK0.38%$7M459.8K
46NGM BIOPHARMACEUTICALS INCCOM0.37%$7M500.0K
47MISTMILESTONE PHARMACEUTICALS INCOM0.36%$6M698.9K
48ALTALTIMMUNE INCCOM NEW0.36%$6M500.0K
49COGTCOGENT BIOSCIENCES INCCOM0.36%$6M425.0K
50RAIN THERAPEUTICS INCCOM0.32%$6M1.18M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.